Targeting FGL2 in glioma immunosuppression and malignant progression

Xiaoyu Ma; Hongtao Zhu; Lidong Cheng; Xin Chen; Kai Shu; Suojun Zhang

doi:10.3389/fonc.2022.1004700

Targeting FGL2 in glioma immunosuppression and malignant progression

Front Oncol. 2022 Oct 13:12:1004700. doi: 10.3389/fonc.2022.1004700. eCollection 2022.

Authors

Xiaoyu Ma¹, Hongtao Zhu¹, Lidong Cheng¹, Xin Chen², Kai Shu¹, Suojun Zhang¹

Affiliations

¹ Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Abstract

Glioblastoma (GBM) is the most malignant type of glioma with the worst prognosis. Traditional therapies (surgery combined with radiotherapy and chemotherapy) have limited therapeutic effects. As a novel therapy emerging in recent years, immunotherapy is increasingly used in glioblastoma (GBM), so we expect to discover more effective immune targets. FGL2, a member of the thrombospondin family, plays an essential role in regulating the activity of immune cells and tumor cells in GBM. Elucidating the role of FGL2 in GBM can help improve immunotherapy efficacy and design treatment protocols. This review discusses the immunosuppressive role of FGL2 in the GBM tumor microenvironment and its ability to promote malignant tumor progression while considering FGL2-targeted therapeutic strategies. Also, we summarize the molecular mechanisms of FGL2 expression on various immune cell types and discuss the possibility of FGL2 and its related mechanisms as new GBM immunotherapy.

Keywords: FGL2; glioma microenvironment; immune checkpoint molecules; immunotherapy; resident immune cell.

Publication types

Review